Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - piperacillin sodium, quantity: 2.085 g (equivalent: piperacillin, qty g); tazobactam sodium, quantity: 268.3 mg (equivalent: tazobactam, qty mg) - injection, powder for - excipient ingredients: - piperacillin/tazobactam kabi is indicated in the treatment of serious bacterial infections caused by susceptible strains of beta-lactamase producing organisms in the conditions listed below: 1. lower respiratory tract infections. 2. urinary tract infections (complicated and uncomplicated). 3. intra-abdominal infections. 4. skin and skin structure infections. 5. bacterial septicaemia. 6. gynaecological infections.,,children under the age of 12 years:,in hospitalised children aged 2 to 12 years, piperacillin/tazobactam kabi injection is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in this indication for paediatric patients below the age of 2 years.,while piperacillin/tazobactam kabi injection is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta-lactamase producing piperacillin-resistant organisms. appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infection to determine their susceptibilities to piperacillin/tazobactam. therapy with piperacillin/tazobactam, however, may be initiated before results of such tests are known when there is a reason to believe the infection may involve any of the beta-lactamase producing organisms listed above; however, once these results become available, appropriate therapy should be continued.,in serious infections, presumptive therapy with piperacillin/tazobactam kabi may be initiated before susceptibility test results are available.,combination therapy with piperacillin/tazobactam kabi and aminoglycosides may be used in the treatment of serious infections caused by pseudomonas aeruginosa. both drugs should be used in full therapeutic doses. as soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted.

Μάλτα - Αγγλικά - Malta Medicines Authority

mylan pharmaceuticals limited damastown industrial park mulhuddart dublin15 dublin, ireland - piperacillin, tazobactam - powder for solution for infusion or injection - piperacillin 2 g tazobactam 0.25 g - antibacterials for systemic use

Μάλτα - Αγγλικά - Malta Medicines Authority

mylan pharmaceuticals limited damastown industrial park mulhuddart dublin15 dublin, ireland - piperacillin, tazobactam - powder for solution for infusion - piperacillin 4 g tazobactam 0.5 g - antibacterials for systemic use

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - piperacillin sodium 2.085 g equivalent to piperacillin 2g; tazobactam sodium 0.2683 g equivalent to tazobactam 0.25g - powder for injection - active: piperacillin sodium 2.085 g equivalent to piperacillin 2g tazobactam sodium 0.2683 g equivalent to tazobactam 0.25g - piperacillin/ tazobactam is indicated for the treatment of the following systemic and/or local bacterial infections in which susceptible organisms have been detected or are suspected: 1. lower respiratory tract infections 2. urinary tract infections (complicated and uncomplicated) 3. intra-abdominal infections 4. skin and skin structure infections 5. bacterial septicaemia 6. gynaecological infections 7. bacterial infections in neutropenic patients. full therapeutic doses of piperacillin/ tazobactam kabi plus an aminoglycoside should be used. 8. bone and joint infections 9. polymicrobic infections: piperacillin/tazobactam kabi is indicated for polymicrobic infections including those where aerobic and anaerobic organisms are suspected (intra-abdominal, skin and skin structure, upper and lower respiratory tract, gynaecological). children under the age of 12 years: in hospitalised children aged 2 to 12 years, piperacillin/ tazobactam is indicated for the treatment of serious intra-abdominal infections.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - piperacillin sodium 4.17 g equivalent to piperacillin 4g; tazobactam sodium 0.5366 g equivalent to tazobactam 0.5g - powder for injection - active: piperacillin sodium 4.17 g equivalent to piperacillin 4g tazobactam sodium 0.5366 g equivalent to tazobactam 0.5g - piperacillin/ tazobactam is indicated for the treatment of the following systemic and/or local bacterial infections in which susceptible organisms have been detected or are suspected: 1. lower respiratory tract infections 2. urinary tract infections (complicated and uncomplicated) 3. intra-abdominal infections 4. skin and skin structure infections 5. bacterial septicaemia 6. gynaecological infections 7. bacterial infections in neutropenic patients. full therapeutic doses of piperacillin/ tazobactam kabi plus an aminoglycoside should be used. 8. bone and joint infections 9. polymicrobic infections: piperacillin/tazobactam kabi is indicated for polymicrobic infections including those where aerobic and anaerobic organisms are suspected (intra-abdominal, skin and skin structure, upper and lower respiratory tract, gynaecological). children under the age of 12 years: in hospitalised children aged 2 to 12 years, piperacillin/ tazobactam is indicated for the treatment of serious intra-abdominal infections.

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - piperacillin; tazobactam - powder for solution for infusion - piperacillin and enzyme inhibitor

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - piperacillin monohydrate 4.198 g equivalent to piperacillin sodium 4.2531g equivalent to piperacillin 4.0g;  ; tazobactam 0.5 g equivalent to tazobactam sodium 0.54733g - powder for injection - active: piperacillin monohydrate 4.198 g equivalent to piperacillin sodium 4.2531g equivalent to piperacillin 4.0g   tazobactam 0.5 g equivalent to tazobactam sodium 0.54733g - indicated for the treatment of the following systemic and/or local bacterial infections in which susceptible organisms have been detected or are suspected: 1. lower respiratory tract infections 2. urinary tract infections (complicated and uncomplicated) 3. intra-abdominal infections 4. skin and skin structure infections 5. bacterial septicaemia 6. gynaecological infections 7. bacterial infections in neutropenic patients. full therapeutic doses of pipertaz sandoz plus an aminoglycoside should be used. 8. bone and joint infections 9. polymicrobic infections: pipertaz sandoz is indicated for polymicrobic infections including those where aerobic and anaerobic organisms are suspected (intra-abdominal, skin and skin structure, upper and lower respiratory tract, gynaecological). children under the age of 12 years in hospitalised children aged 2 to 12 years, pipertaz sandoz is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in this indication for paediatric patients below the age of 2 years.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

x-gen pharmaceuticals, inc. - piperacillin sodium (unii: m98t69q7hp) (piperacillin anhydrous - unii:9i628532gx) - piperacillin anhydrous 3 g in 20 ml

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

stravencon ltd - piperacillin sodium; tazobactam sodium - powder for solution for infusion - 4/0.5 gram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; piperacillin and enzyme inhibitor

Βέλγιο - Αγγλικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - piperacillin sodium 2,085 g - eq. piperacillin 2 g; tazobactam sodium 268,3 mg - eq. tazobactam 250 mg - powder for solution for infusion - 2 g - 250 mg - piperacillin sodium 2.085 g; tazobactam sodium 268.3 mg - piperacillin and enzyme inhibitor